[Federal Register Volume 88, Number 137 (Wednesday, July 19, 2023)]
[Rules and Regulations]
[Page 46073]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-15249]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[Docket No. DEA-716]


Schedules of Controlled Substances: Placement of Brorphine in 
Schedule I; Correction

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final order; correction. Correcting amendment.

-----------------------------------------------------------------------

SUMMARY: On March 6, 2023, the Drug Enforcement Administration 
published a final order placing 1-(1-(1-(4-bromophenyl)ethyl)piperidin-
4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 
brorphine), including its isomers, esters, ethers, salts, and salts of 
isomers, esters, and ethers whenever the existence of such isomers, 
esters, ethers, and salts is possible within the specific chemical 
designation, in schedule I of the Controlled Substances Act. In an 
amendatory instruction, the document incorrectly designated certain 
paragraphs. This document corrects that instruction.

DATES: This correcting amendment is effective July 19, 2023, and is 
applicable beginning March 6, 2023.

FOR FURTHER INFORMATION CONTACT: Dr. Terrence L. Boos, Drug and 
Chemical Evaluation Section, Diversion Control Division, Drug 
Enforcement Administration; Telephone: (571) 362-3249.

SUPPLEMENTARY INFORMATION: In FR Doc. 2023-04364, appearing on page 
13692 in the Federal Register of Monday, March 6, 2023 (88 FR 13692), 
the following correction is made:


Sec.  1308.11  [Corrected]

0
1. On page 13694, in the third column, amendatory instruction number 2 
is corrected to read as follows:
0
``2. In Sec.  1308.11:
0
a. Redesignate paragraphs (b)(22) through (b)(92) as (b)(23) through 
(b)(93);''
0
b. Add a new paragraph (b)(22);
0
c. Remove and reserve paragraph (h)(49).
    The addition reads as follows:''

Signing Authority

    This document of the Drug Enforcement Administration was signed on 
July 5, 2023, by Administrator Anne Milgram. That document with the 
original signature and date is maintained by DEA. For administrative 
purposes only, and in compliance with requirements of the Office of the 
Federal Register, the undersigned DEA Federal Register Liaison Officer 
has been authorized to sign and submit the document in electronic 
format for publication, as an official document of DEA. This 
administrative process in no way alters the legal effect of this 
document upon publication in the Federal Register.

Scott Brinks,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2023-15249 Filed 7-18-23; 8:45 am]
BILLING CODE P